Detection and characterization of a transport system mediating cysteamine entry into human fibroblast lysosomes. Specificity for aminoethylthiol and aminoethylsulfide derivatives
- PMID: 7836377
- DOI: 10.1074/jbc.270.3.1179
Detection and characterization of a transport system mediating cysteamine entry into human fibroblast lysosomes. Specificity for aminoethylthiol and aminoethylsulfide derivatives
Abstract
The uptake of [3H]cysteamine by Percoll-purified human fibroblast lysosomes was investigated to determine whether lysosomes contain a transport system recognizing cysteamine. Lysosomal cysteamine uptake is a Na(+)-independent process which rapidly attains a steady state within 1 min at pH 7.0 and 37 degrees C. A biphasic Arrhenius plot is observed for cysteamine uptake, giving a Q10 of 2.2 from 17 to 26 degrees C and a Q10 of 1.2 from 27 to 35 degrees C. The rate of lysosomal cysteamine uptake is maximal at pH 8.2, half-maximal at pH 6.8, and declines approximately 50-fold from the maximum to show very little transport at pH 5.0. Cysteamine uptake into fibroblast lysosomes displays complete saturability with a Km of 0.88 mM and Vmax of 1410 pmol of beta-N-acetylhexosaminidase/min at pH 7.0 and 37 degrees C. Analog inhibition studies demonstrated that all analogs recognized thus far by the cysteamine carrier are either aminothiols or aminosulfides and contain an amino group and sulfur atom separated by a carbon chain, 2 carbon atoms in length. The Ki constants for these analogs as competitive inhibitors of lysosomal cysteamine uptake are 2-(ethylthio)ethylamine (0.64 mM), 1-amino-2-methyl-2-propanethiol (0.74 mM), 2-dimethylaminoethanethiol (0.87 mM), thiocholine (1.6 mM), and bis(2-aminoethyl)sulfide (4.9 mM). L-Cysteine, D-penicillamine, and analogs lacking either a sulfur atom or amino group are not recognized by the cysteamine carrier including ethanolamine, choline, taurine, beta-mercaptoethanol, ethylenediamine, cadaverine, spermine, spermidine, histamine, dopamine, and 3-hydroxytyramine. In a cystine-depletion assay, a 2-h exposure of cystinotic fibroblasts to 1 mM 1-amino-2-methyl-2-propanethiol lowers cell cystine levels to the same low level obtained with cysteamine. Thus, all four aminothiols, known to deplete cystinotic fibroblasts of their accumulated cystine, are recognized as substrates by the lysosomal cysteamine carrier, suggesting the importance of this transporter in the delivery of aminothiols to the lysosomal compartment.
Similar articles
-
A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis.J Cell Biol. 1990 Feb;110(2):327-35. doi: 10.1083/jcb.110.2.327. J Cell Biol. 1990. PMID: 2404990 Free PMC article.
-
Important differences in cationic amino acid transport by lysosomal system c and system y+ of the human fibroblast.J Biol Chem. 1987 Nov 5;262(31):15011-8. J Biol Chem. 1987. PMID: 3499437
-
Detection and characterization of a nucleoside transport system in human fibroblast lysosomes.J Biol Chem. 1989 Mar 25;264(9):4850-6. J Biol Chem. 1989. PMID: 2925670
-
Cystine depletion of cystinotic cells by aminothiols.Proc R Soc Med. 1977;70 Suppl 3(Suppl 3):37-40. doi: 10.1177/00359157770700S314. Proc R Soc Med. 1977. PMID: 122669 Free PMC article. Review. No abstract available.
-
Cysteamine revisited: repair of arginine to cysteine mutations.J Inherit Metab Dis. 2017 Jul;40(4):555-567. doi: 10.1007/s10545-017-0060-4. Epub 2017 Jun 22. J Inherit Metab Dis. 2017. PMID: 28643139 Free PMC article. Review.
Cited by
-
Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice.J Am Heart Assoc. 2021 Sep 21;10(18):e017524. doi: 10.1161/JAHA.120.017524. Epub 2021 Sep 8. J Am Heart Assoc. 2021. PMID: 34493066 Free PMC article.
-
Cysteamine prevents inhibition of adenylate kinase caused by cystine in rat brain cortex.Metab Brain Dis. 2009 Dec;24(4):723-31. doi: 10.1007/s11011-009-9141-x. Epub 2009 May 13. Metab Brain Dis. 2009. PMID: 19437111
-
New aspects of the pathogenesis of cystinosis.Pediatr Nephrol. 2003 Mar;18(3):207-15. doi: 10.1007/s00467-003-1077-5. Epub 2003 Feb 27. Pediatr Nephrol. 2003. PMID: 12644911 Review.
-
Cysteamine prevents inhibition of adenylate kinase caused by cystine in rat brain cortex.Metab Brain Dis. 2009 Sep;24(3):373-81. doi: 10.1007/s11011-009-9142-9. Epub 2009 Aug 18. Metab Brain Dis. 2009. PMID: 19688256
-
Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.Br J Clin Pharmacol. 2003 Nov;56(5):520-5. doi: 10.1046/j.1365-2125.2003.01927.x. Br J Clin Pharmacol. 2003. PMID: 14651726 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous